3. >>Deals

Takeda Poised To Move Into Pharma Top 10 With Shire Combination

 
• By Kevin Grogan

Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well. 

Ladder
Shire will climb into the pharma top 10 with Takeda deal • Source: Shutterstock

With Shire PLC management finally recommending a $62.4bn offer from Takeda Pharmaceutical Co. Ltd., the Japanese pharma is poised to move into the top 10 pharmaceutical companies club.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business